:: Library Catalog

Image de couverture de livre

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Manya Prasad, Tushar Prabhakar, Shiv Kumar Sarin
Format:	Artículo Open Access
Publié:	Wiley 2024
Sujets:	Alimentary Pharmacology & Therapeutics
Accès en ligne:	https://onlinelibrary.wiley.com/doi/10.1111/apt.17921
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Editorial: The tsunami of steatotic liver disease in India, the Asia‐Pacific region and the world
par: Abdel‐Aziz Shaheen, et autres
Publié: (2024)

Editorial: Crystalising the burden of steatotic liver disease—Authors' reply
par: Carolin V. Schneider, et autres
Publié: (2024)

Editorial: Updated epidemiology of steatotic liver disease in people withHIVin the United States—Authors' reply
par: Samer Gawrieh, et autres
Publié: (2024)

Editorial: Updated epidemiology of steatotic liver disease in people with HIV in the United States
par: Richie Manikat, et autres
Publié: (2024)

Editorial: Quantity is important! Authors' reply
par: Marika Rudler, et autres
Publié: (2024)

Letter: Potential impact ofHelicobacter pyloriinfection on oesophageal disorders in chronic liver disease—Authors' reply
par: Francisco Idalsoaga, et autres
Publié: (2024)

Editorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice. Authors' reply
par: Eunice X. X. Tan, et autres
Publié: (2024)

Editorial: Mortality in immune‐mediated inflammatory diseases during early adulthood—Authors' reply
par: Mikkel Malham, et autres
Publié: (2024)

Editorial: Using machine learning to predict significant fibrosis in metabolic dysfunction‐associated steatotic liver disease
par: Richie Manikat, et autres
Publié: (2024)

Editorial: Another brick in the CDST wall: Authors' reply
par: Kyuwon Kim, et autres
Publié: (2024)

Editorial: Recompensation in PBC is good. But is it good enough? Authors' reply
par: Benedikt Silvester Hofer, et autres
Publié: (2024)

Editorial: Infliximab induction therapy in paediatric Crohn's disease — A cost‐effective strategy? Authors' reply
par: Stephanie A. Vuijk, et autres
Publié: (2024)

Letter: Algorithmic NIT approaches to identify advanced liver fibrosis in patients with MASLD: Authors' reply
par: Stuart McPherson, et autres
Publié: (2024)

Editorial: The microbiome and gastric mucosal protection in aspirin users—Authors' reply
par: Nina Løn, et autres
Publié: (2024)

Letter: Thioguanine, an under‐utilised option in inflammatory bowel disease? Authors' reply
par: Abhinav Vasudevan, et autres
Publié: (2024)

Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction‐associated steatotic liver disease
par: Nabil Noureddin, et autres
Publié: (2024)

Prevalence of at‐risk MASH, MetALD and alcohol‐associated steatotic liver disease in the general population
par: Carolin V. Schneider, et autres
Publié: (2024)

Editorial: Unravelling real‐world impact of second‐line therapies in primary biliary cholangitis—Time to change our targets? Authors' reply
par: C. M. Fernández‐Rodríguez, et autres
Publié: (2024)

Cardiometabolic criteria as predictors and treatment targets of liver‐related events and cardiovascular events in metabolic dysfunction‐associated steatotic liver disease
par: Nobuharu Tamaki, et autres
Publié: (2024)

Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality
par: Nobuharu Tamaki, et autres
Publié: (2024)

Editorial: Can we predict or not predict response to hypnotherapy? That is the question. Authors' reply
par: Dipesh H. Vasant, et autres
Publié: (2024)

Editorial: Revisit the causes and long‐term outcomes in cirrhosis patients—Authors' reply
par: Linda Henry, et autres
Publié: (2024)

Machine learning improves the prediction of significant fibrosis in Asian patients with metabolic dysfunction‐associated steatotic liver disease – The Gut and Obesity in Asia (GO‐ASIA) Study
par: Nipun Verma, et autres
Publié: (2024)

Editorial: Enhancing frailty assessment in liver transplantation candidates—The role of the Duke Activity Status Index (DASI) in predicting mortality and guiding prehabilitation. Authors' reply
par: Matthew J. Armstrong, et autres
Publié: (2024)

Editorial: How often can we get the right diagnosis after bone marrow transplant in patients with abnormal liver function tests? Authors' reply
par: Maria Gabriela Fernandes Dezan, et autres
Publié: (2024)

The overlap with metabolic dysfunction‐associated steatotic liver disease negatively affects outcomes of primary biliary cholangitis
par: María Hernández‐Pérez, et autres
Publié: (2024)

Editorial: Genetics for non‐invasive risk stratification—Finding the needle in the haystack? Authors' reply
par: Lana Bridi, et autres
Publié: (2024)

Editorial: Sonographic assessment of colonic content—A new tool for constipation? Authors' reply
par: R. M. Mathias, et autres
Publié: (2024)

Editorial: Emulsifiers and thickeners in our food—Do they alter gut permeability? Authors' reply
par: Jessica A. Fitzpatrick, et autres
Publié: (2024)

Editorial: High qHBsAg—Is it a good or bad signal? Authors' reply
par: Hsin‐Che Lin, et autres
Publié: (2024)

Editorial: Hepatitis C virus eradication improves skeletal muscle mass—Authors' reply
par: Marta Paula Pereira Coelho, et autres
Publié: (2024)

Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study
par: Yewan Park, et autres
Publié: (2024)

Systematic review with meta‐analysis: Steatosis severity and subclinical atherosclerosis in metabolic dysfunction‐associated steatotic liver disease
par: Mohamad Jamalinia, et autres
Publié: (2024)

Editorial: Mucosal healing with steroids—Once upon a time in ulcerative colitis. Authors' reply
par: Tomohiro Fukuda, et autres
Publié: (2024)

Editorial: Sequencing rescue therapy for acute severe ulcerative colitis—Ready for revision? Authors' reply
par: María José García, et autres
Publié: (2024)

Editorial: Eosinophilic oesophagitis coming of age—Increasing frequency and wider age range—Authors' reply
par: Akshatha Kiran, et autres
Publié: (2024)

Editorial: Reading the cholate—A new gateway to portal hypertension and oesophageal varices: Authors' reply
par: Tarek Hassanein, et autres
Publié: (2024)

Letter: Irritable bowel syndrome and antibiotics—Authors' reply
par: Kyle Staller, et autres
Publié: (2024)

Editorial: Towards optimal thiopurine therapy for inflammatory bowel disease—authors' reply
par: Abhinav Vasudevan, et autres
Publié: (2024)

Poor accuracy and sustainability of the first‐step FIB4 EASL pathway for stratifying steatotic liver disease risk in the general population
par: Antonio De Vincentis, et autres
Publié: (2024)